SubsidieMeestersAmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant
AmbiJet is a groundbreaking plasma-based technology that effectively eliminates bacteria on dental implants, preventing reinfection and promoting better oral and overall health.
Projectdetails
Introduction
Regular dental check-ups and treatments not only ensure a beautiful smile, but also contribute to good general health. A healthy oral cavity strengthens the immune system and acts as a barrier against various diseases, including:
- Heart-related diseases
- Kidney-related diseases
- Lung-related diseases
- Diabetes
Current Challenges
There is currently no effective solution to treat the 16.3 million infected dental implants in the EU as of 2019.
The Solution
Freiburger Medizintechnik GmbH has developed the solution dentists are looking for: a disruptive technology for highly effective infection control to fight peri-implantitis.
AmbiJet Technology
AmbiJet is the world's first and only plasma-based technology with the ability to kill bacteria on dental implants in-situ.
Key Features
- Disrupts the status quo of medical technologies by preventing the reinfection of disinfected surfaces.
- Shows maximum effectiveness without side or adverse effects.
- Eliminates the need for pharmacological and chemical substances.
Benefits
AmbiJet reduces inflammation, saves dental implants, and helps patients live a healthier life.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.389.062 |
| Totale projectbegroting | € 1.984.375 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- FREIBURGER MEDIZINTECHNIK GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Skin micro-injectorBold-Jet aims to revolutionize needle-free injections with a microjet device that enhances safety, minimizes invasiveness, and improves patient adherence to treatments. | ERC POC | € 150.000 | 2022 | Details |
Bacteria Biofilm as bio-factory for tissue regenerationBIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes. | EIC Pathfinder | € 2.903.862 | 2023 | Details |
A metagenomic-based precision-medicine tool for personalized diagnosis, prognosis and treatment of oral diseasesPreBiomicsPMT aims to develop an automated precision-medicine test using metagenomics and AI to assess peri-implant plaque microbiomes, enhancing diagnosis and treatment for dental implant patients. | EIC Transition | € 2.461.900 | 2023 | Details |
Integrated needle-free injection and sensing using opto-microfluidicsiSENS is developing BoldJet, a portable needle-free injector using thermocavitation microjets for precise, safe, and environmentally friendly medication delivery, enhancing patient compliance and healthcare outcomes. | EIC Transition | € 2.499.999 | 2024 | Details |
Skin micro-injector
Bold-Jet aims to revolutionize needle-free injections with a microjet device that enhances safety, minimizes invasiveness, and improves patient adherence to treatments.
Bacteria Biofilm as bio-factory for tissue regeneration
BIOACTION aims to transform biofilm-associated infections into a resource for tissue regeneration using functionalized bio-hydrogels and engineered liposomes, enhancing implant technology and health outcomes.
A metagenomic-based precision-medicine tool for personalized diagnosis, prognosis and treatment of oral diseases
PreBiomicsPMT aims to develop an automated precision-medicine test using metagenomics and AI to assess peri-implant plaque microbiomes, enhancing diagnosis and treatment for dental implant patients.
Integrated needle-free injection and sensing using opto-microfluidics
iSENS is developing BoldJet, a portable needle-free injector using thermocavitation microjets for precise, safe, and environmentally friendly medication delivery, enhancing patient compliance and healthcare outcomes.